AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,223,332 | -5.6% | 100,603 | -2.4% | 0.01% | +10.0% |
| Q2 2023 | $1,295,225 | +10.1% | 103,123 | -2.8% | 0.01% | 0.0% |
| Q1 2023 | $1,176,582 | +240.1% | 106,094 | +229.5% | 0.01% | +233.3% |
| Q2 2022 | $346,000 | -8.2% | 32,199 | -19.0% | 0.00% | +50.0% |
| Q1 2022 | $377,000 | -11.3% | 39,748 | +8.1% | 0.00% | 0.0% |
| Q4 2021 | $425,000 | -73.5% | 36,755 | -78.1% | 0.00% | -80.0% |
| Q3 2021 | $1,602,000 | -8.6% | 167,742 | -7.8% | 0.01% | 0.0% |
| Q2 2021 | $1,753,000 | -4.9% | 181,925 | -2.5% | 0.01% | -16.7% |
| Q1 2021 | $1,844,000 | -43.2% | 186,560 | +32.6% | 0.01% | -40.0% |
| Q4 2020 | $3,248,000 | +964.9% | 140,698 | +552.2% | 0.02% | +900.0% |
| Q3 2020 | $305,000 | -57.5% | 21,572 | -59.1% | 0.00% | -66.7% |
| Q1 2019 | $718,000 | +37.5% | 52,777 | -3.3% | 0.01% | +50.0% |
| Q4 2018 | $522,000 | -84.5% | 54,554 | -80.4% | 0.00% | -81.8% |
| Q3 2018 | $3,364,000 | -17.3% | 278,274 | +6.8% | 0.02% | -18.5% |
| Q2 2018 | $4,068,000 | +19.0% | 260,458 | +14.6% | 0.03% | +237.5% |
| Q1 2018 | $3,419,000 | +13.2% | 227,353 | +8.3% | 0.01% | +14.3% |
| Q4 2017 | $3,021,000 | -25.8% | 209,883 | -22.2% | 0.01% | -30.0% |
| Q3 2017 | $4,069,000 | +59.3% | 269,908 | +6.4% | 0.01% | +42.9% |
| Q2 2017 | $2,555,000 | +25.3% | 253,775 | -11.2% | 0.01% | +16.7% |
| Q1 2017 | $2,039,000 | +34.0% | 285,913 | -6.6% | 0.01% | +50.0% |
| Q4 2016 | $1,522,000 | -39.9% | 306,205 | +2.2% | 0.00% | -50.0% |
| Q1 2016 | $2,532,000 | -10.2% | 299,607 | +3.0% | 0.01% | 0.0% |
| Q4 2015 | $2,821,000 | +32.1% | 290,868 | +90.6% | 0.01% | +14.3% |
| Q3 2015 | $2,135,000 | +2441.7% | 152,635 | +1418.2% | 0.01% | – |
| Q4 2014 | $84,000 | +50.0% | 10,054 | -39.9% | 0.00% | – |
| Q2 2014 | $56,000 | +14.3% | 16,717 | -30.6% | 0.00% | – |
| Q1 2014 | $49,000 | +4.3% | 24,087 | +18.9% | 0.00% | – |
| Q4 2013 | $47,000 | +14.6% | 20,264 | +12.4% | 0.00% | – |
| Q3 2013 | $41,000 | +28.1% | 18,031 | +31.2% | 0.00% | – |
| Q2 2013 | $32,000 | – | 13,746 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |